Publication: Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial
No Thumbnail Available
Identifiers
Date
2022-05-05
Authors
Gebhart, G.
Keyaerts, M.
Guiot, T.
Flamen, P.
Ruiz Borrego, M.
Stradella, A.
Bermejo De Las Heras, B.
Escriva de Romani, S.
Calvo-Martinez, L.
Ribelles Entrena, N.
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Metrics
Export
